New rabies treatment noninferior to standard PEP.

New rabies treatment noninferior to standard PEP.A new human rabies antibody was noninferior to a currently administered immunoglobulin product for post-exposure prophylaxis, or PEP, researchers said. In fact, the geometric mean concentration (GMC) of rabies antibodies (RVNA) in patients who were given the new antibody (SII RMAb) — which was developed by recombinant DNA technology — was more than four times that of those receiving human rabies immunoglobulin (HRIG), they wrote in Clinical Infectious Diseases. “This pivotal study demonstrated that a PEP regimen of SII RMAb and rabies vaccine produced RVNA activity on day 14 that was noninferior to that of HRIG more